Trial Profile

Phase 2a, Multicenter, Masked, Randomized, Comparator Controlled Study Evaluating iSONEP™ as Monotherapy or Adjunctive Therapy to Lucentis/Avastin/Eylea Versus Lucentis/Avastin/Eylea Alone for Treatment of Subjects With Choroidal Neovascularization (CNV) Secondary to Age-related Macular Degeneration (AMD)

Status: Completed

Phase of Trial: Phase II

Latest Information Update: 14 Jan 2020

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Sonepcizumab (Primary) ; Aflibercept; Bevacizumab; Ranibizumab
Indications Choroidal neovascularisation; Wet age-related macular degeneration
Focus Therapeutic Use
Acronyms Nexus
Sponsors Lpath

15 Sep 2015 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
20 May 2015 Full results will be presented at the American Academy of Ophthalmology in November 2015, according to Lpath media release.
20 May 2015 Results published in the Media Release.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com